Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price target hoisted by Barclays from $90.00 to $98.00 in a research note published on Wednesday, The Fly reports. Several other analysts also recently commented on the stock. SVB Securities raised their price objective on shares of Reata Pharmaceuticals from $35.00 to $75.00 in a research report […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) shares gapped down before the market opened on Wednesday after Cantor Fitzgerald lowered their price target on the stock from $138.00 to $110.00. The stock had previously closed at $105.37, but opened at $89.50. Reata Pharmaceuticals shares last traded at $83.06, with a volume of 1,146,539 shares traded. […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price target increased by research analysts at Barclays from $90.00 to $98.00 in a note issued to investors on Wednesday, The Fly reports. Barclays‘s price target points to a potential upside of 8.43% from the stock’s previous close. Several other analysts also recently commented on the stock. […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its target price raised by Stifel Nicolaus from $105.00 to $115.00 in a research report report published on Thursday, The Fly reports. A number of other research analysts have also commented on RETA. Citigroup lifted their price objective on shares of Reata Pharmaceuticals from $53.00 to $120.00 and […]